Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer

Comments
Loading...
  • Puma Biotechnology Inc PBYI announced an agreement with Takeda Pharmaceutical Co Ltd TAK to license the worldwide research and development and commercial rights to alisertib for cancer indications.
  • Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia.
  • Under the terms of the agreement, Puma will assume sole responsibility for the global development and commercialization of alisertib. 
  • Takeda will receive an upfront license fee of $7 million and is eligible to receive potential future milestone payments of up to $287.3 million and tiered sales-based royalty payments.
  • Puma initially intends to focus the development of alisertib on metastatic estrogen receptor-positive (ER-positive) HER2-negative breast cancer, triple-negative breast cancer, and small cell lung cancer. 
  • In previous trials, Alisertib has demonstrated meaningful clinical activity in these populations, most notably in ER-positive breast cancer patients previously treated with a CDK4/6 inhibitor. 
  • Alisertib was also previously tested in small cell lung cancer in a Phase 2 trial as a single agent and a Phase 2 trial in combination with paclitaxel compared to paclitaxel monotherapy.
  • Price Action: PBYI shares are down 1.20% at $2.46 during the market session on the last check Wednesday.
PBYI Logo
PBYIPuma Biotechnology Inc
$3.32-5.68%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum61.44
Growth0.01
Quality-
Value77.84
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: